 Immunotherapy, Adoptive
"Immunotherapy, Adoptive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
| Descriptor ID |
D016219
|
| MeSH Number(s) |
E02.095.465.425.400.330.050.400 E05.478.550.520.050.400
|
| Concept/Terms |
Immunotherapy, Adoptive- Immunotherapy, Adoptive
- Immunotherapy, Adoptive Cellular
- Adoptive Immunotherapy
- Adoptive Immunotherapies
- Immunotherapies, Adoptive
- Cellular Immunotherapy, Adoptive
- Adoptive Cellular Immunotherapies
- Cellular Immunotherapies, Adoptive
- Immunotherapies, Adoptive Cellular
- Adoptive Cellular Immunotherapy
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy, Adoptive".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy, Adoptive".
This graph shows the total number of publications written about "Immunotherapy, Adoptive" by people in this website by year, and whether "Immunotherapy, Adoptive" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 2 | 0 | 2 | | 1998 | 1 | 0 | 1 | | 2001 | 1 | 1 | 2 | | 2002 | 2 | 2 | 4 | | 2003 | 2 | 0 | 2 | | 2004 | 2 | 1 | 3 | | 2005 | 0 | 1 | 1 | | 2007 | 1 | 0 | 1 | | 2008 | 2 | 1 | 3 | | 2009 | 1 | 1 | 2 | | 2010 | 2 | 1 | 3 | | 2011 | 1 | 0 | 1 | | 2012 | 3 | 3 | 6 | | 2013 | 4 | 1 | 5 | | 2014 | 8 | 4 | 12 | | 2015 | 6 | 4 | 10 | | 2016 | 10 | 3 | 13 | | 2017 | 7 | 3 | 10 | | 2018 | 12 | 3 | 15 | | 2019 | 19 | 5 | 24 | | 2020 | 16 | 4 | 20 | | 2021 | 17 | 13 | 30 | | 2022 | 6 | 17 | 23 | | 2023 | 4 | 25 | 29 | | 2024 | 14 | 9 | 23 | | 2025 | 33 | 1 | 34 | | 2026 | 3 | 1 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunotherapy, Adoptive" by people in Profiles.
-
Schultz L, McNerney K, Lamble AJ, Calkoen FG, Baruchel A, Ceppi F, Curran KJ, Gore L, Lamb M, Maude SL, Pulsipher MA, Qayed M, Ramakrishna S, Rheingold SR, Rossig C, Silbert SK, Steineck A, Summers C, Capitini CM, Bhojwani D, Gardner RA, Ghorashian S, Shah NN. The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer. Nat Rev Clin Oncol. 2026 Apr; 23(4):260-278.
-
Moreno-Castaño AB, Fernández S, Brillembourg H, Iraola G, Moreno DF, Ventosa-Capell H, Martinez-Sanchez J, De Moner B, Molina P, Ramos A, Palomo M, Gómez-Ramírez P, Ortiz-Maldonado V, Martínez-Cibrián N, Delgado J, Oliver-Caldés A, Fernández de Larrea C, Salas MQ, Urbano Á, Téllez A, Nicolás JM, Juan M, González-Navarro A, Penack O, Escolar G, Carreras E, Fernández-Avilés F, Castro P, Diaz-Ricart M. m-EASIX (better than EASIX) predicts severe CAR T-cell toxicities, worse overall survival, and discriminates cytokine release syndrome from sepsis. Front Immunol. 2025; 16:1664788.
-
Ang MJY, Metzloff AE, Thatte AS, Mitchell MJ. Lipid nanoparticles for engineering next generation CAR T cell immunotherapy. Nanoscale Horiz. 2026 Jan 05; 11(1):22-36.
-
Sirlanci M, Albers D, Kwak J, Smith C, Bennett TD, Bair SM. Navigating the landscape of personalized oncology: overcoming challenges and expanding horizons with computational modeling. J Am Med Inform Assoc. 2026 Jan 01; 33(1):242-251.
-
DeGolier KR, Pham-Danis C, Burciaga SD, Walsh ZH, Brzezinski C, Novak AJ, Leach L, Cimons J, Li W, Zhongyu Z, Dimitrov D, Scott-Browne JP, Kohler ME, Fry TJ. Rational redesign of antigen binding domain improves in vivo efficacy of the CD22-CAR. Mol Ther. 2026 Apr 01; 34(4):2175-2188.
-
Loftus TJ, Cho JY, Meraz M, Dhippayom T, Bock AM, Wagner CB, Thavorn K, Chaiyakunapruk N. Cost-effectiveness of chimeric antigen receptor T-cell therapy for relapsed or refractory large B-cell lymphoma: a systematic review and meta-analysis. J Med Econ. 2025 Dec; 28(1):2216-2235.
-
Naik S, Aplenc R, Baumeister SHC, Becilli M, Bhagwat AS, Bonifant CL, Budde LE, Chien CD, Curran KJ, Daniyan AF, Dreyzin A, Gardner RA, Ghorashian S, Gottschalk S, Hill LC, Kohler ME, Lamble A, Locatelli F, Mamonkin M, Omer B, Park JH, Quintarelli C, Rambaldi B, Richards RM, Sallman DA, Sauer T, Shah NN, Subklewe M, Summers C, Tasian SK, Taylor N, Tettamanti S, Verneris MR, Velasquez MP, Gill SI. International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML. Blood Adv. 2025 Dec 09; 9(23):6047-6058.
-
Rankin AW, Pham-Danis C, Novak AJ, Danis E, Fry TJ, Kohler ME. Increased NFAT activity with dual CAR stimulation in CD19xCD22 CAR T-cells is associated with decreased exhaustion and improved survival. J Immunother Cancer. 2025 Nov 13; 13(11).
-
Rangarajan HG, Satwani P, Herr MM, Chen M, Martens MJ, Wudhikarn K, John S, Fabrizio VA, Hsieh EM, Kelkar AH, Doherty E, Marks DI, Ringden O, Friend B, Kelly MS, Farhadfar N, Prestidge T, Hossain NM, Liu H, Hashmi S, Modi D, Winestone LE, El Boghdadly Z, Murthy HS, Perales MA, Chemaly RF, Dandoy CE, Hill JA, Huppler A, Riches M, Auletta JJ. Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis. Blood Adv. 2025 Nov 11; 9(21):5489-5500.
-
Epstein-Peterson ZD, Lionel AC, Joseph A, Drill E, Atallah-Yunes SA, Brooks TR, Chong EA, Chong ER, Dela Cruz J, Frank MJ, Ip A, Iqbal M, Jacobson CA, Kamdar MK, Karmali R, Beyar-Katz O, Maddocks KJ, Matasar MJ, McLoughlin D, Merryman RW, Munoz JL, Navalekar R, Rhodes J, Riedell PA, Ryan CE, Salles G, Sauter CS, Sawalha Y, Sharma S, Shouval R, Shukla N, Therwhanger D, van Besien H, Varon B, Wang Y, Yamshon S, Zelenetz AD, Palomba ML, Jain P, Kumar A. Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis. Blood Adv. 2025 Nov 11; 9(21):5654-5662.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|